We are international
Donate
TEXT SIZE   


Phase I/II VELCADE® Clinical Trials
05.01.08

US TRIALS

  • Study of Velcade and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma (UARK 2004-22)
    Little Rock, AR

  • Phase I/II trial of autologous peripheral blood progenitor cell transplantation with VELCADE maintenance as treatment for intermediate- and advanced-stage multiple myeloma (i34103-050)
    Los Angeles, CA

  • Phase I/II Study of Adjuvant Bortezomib as Maintenance Therapy After Autologous Peripheral Blood Stem Cell Transplantation in Patients With Intermediate or Advanced Multiple Myeloma (UCLA-0306106)
    Los Angeles, CA

  • The combination of proteasome inhibition and farnesyltransferase inhibition as therapy for relapsed/refractory malignancies. A Phase I/II trial of bortezomib (VELCADE or PS-341) combined with R115777 (Zarnestra) (VEL-04-112)
    Atlanta, GA

  • Phase I/II open-label study of the safety and efficacy of bortezomib, lenalidomide, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma (X05188)
    Boston, MA - multicenter

  • Phase I/II open-label study of the safety and efficacy of bortezomib, lenalidomide, +/- dexamethasone combination therapy for patients with relapsed or refractory multiple myeloma (X05189)
    Boston, MA - multicenter

  • Phase I/II study of the safety and efficacy of CCI-779 in combination with bortezomib in the treatment of subjects with relapsed and relapsed/refractory multiple myeloma (X05224)
    Boston, MA

  • Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation (06-065)
    Boston, MA - multicenter

  • Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma (06-150)
    Boston, MA - multicenter

  • Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma (06-365)
    Boston, MA

  • Safety and Efficacy Study of GCS-100 in the Treatment of Multiple Myeloma (PR-CS009)
    Cambridge, MA

  • Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients (SCRI MM 14)
    Bethesda, MD- multicenter

  • Phase I/II study of VELCADE, dexamethasone, and Revlimid (lenalidomide) (VDR) versus VELCADE, dexamethasone, cyclophosphamide, and Revlimid (VDCR) in subjects with previously untreated multiple myeloma ((Evolution) C05008)
    Rochester, MN

  • Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma (7365)
    Durham, NC

  • Phase I/II Study of Doxorubicin HCl Liposome, Melphalan, and Bortezomib in Patients With Relapsed or Refractory Stage I-III Multiple Myeloma (CPMC-AAAB6443)
    New York, NY - multicenter

  • Phase I/II Study of Hydroxychloroquine and Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (UPCC-01407)
    Philadelphia, PA

  • Bevacizumab and Bortezomib in Patients With Advanced Malignancy (2006-0764)
    Houston, TX

  • A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma (ATN-224-007)
    multicenter

  • Phase I/II Study of Safety & Efficacy of Perifosine & Bortezomib With or Without Dexamethasone for Multiple Myeloma Patients (Perosifine 218)
    multicenter

FOREIGN TRIALS

  • Phase I/II trial of depsipeptide and VELCADE in patients with relapsed multiple myeloma (2006-VEL-AP-0019)
    Melbourne, Australia

  • A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients with Relapsed Myeloma (06/34)
    Melbourne, Australia

  • Impact of VELCADE on bone turnover markers in multiple myeloma and non-hodgkinís lymphoma (2006-VEL-EU-0031)
    Vejle, Denmark - multicenter

  • An open label, Phase I/II study of VELCADE in multiple myeloma patients undergoing reduced intensity conditioning allogeneic transplantation (VEL-EU-0069)
    multicenter


 related articles